Novo Nordisk (NVO) stock gained 1.85% to close at $45.71 on Tuesday, outperforming the broader market as investors focused on expanding access to the company's Wegovy obesity treatment through a new Medicare program. The advance came even as pricing pressure remains a central concern for the Danish drugmaker.

The U.S.-listed shares advanced while the S&P 500 declined 0.69%, giving Novo Nordisk a notable relative performance advantage during the session. The company's Copenhagen-listed B shares moved in the opposite direction the following day, trading around DKK 293.80 by 09:02 CEST on Wednesday, down 0.86%.

Medicare Access Changes the Equation

At the center of the latest investor debate is Medicare's GLP-1 Bridge program, which began July 1 and is scheduled to run through the end of 2027. The initiative allows eligible Medicare Part D beneficiaries to obtain approved weight-loss medicines for a $50 monthly copay — a payment significantly lower than what many patients could otherwise face when paying out of pocket, potentially making Wegovy accessible to a broader group of eligible Americans. The step is notable because Medicare Part D has historically excluded coverage of drugs prescribed for weight loss alone, which previously left many beneficiaries paying out of pocket or going without treatment.

The program covers both Wegovy tablets and injections, giving Novo Nordisk exposure across its expanding obesity-treatment portfolio. According to information provided by the Centers for Medicare & Medicaid Services, the manufacturer net price under the program is listed at $245 per monthly supply. That price sits alongside other recent Novo Nordisk pricing moves, including its NovoCare direct-to-consumer pharmacy, which lists Wegovy at $499 per month for U.S. cash-paying customers.

That framework creates a complicated trade-off for investors: Novo Nordisk could benefit from higher prescription volumes, but lower realized prices may reduce the financial benefit of each additional patient.

Wegovy Prescriptions Continue Rising

Company data indicates that U.S. demand for Wegovy has been accelerating. By July 17, weekly prescriptions across the Wegovy franchise reached approximately 575,000, with the newly introduced pill accounting for more than 265,000 prescriptions — roughly 46% of total weekly Wegovy volume at the time. Novo Nordisk also reported that cumulative prescriptions for the oral version had passed five million after 30 weeks.

Wegovy's active ingredient, semaglutide, is the same molecule behind Novo Nordisk's diabetes drugs Ozempic and the oral tablet Rybelsus, giving the company established commercial experience with both the compound and an oral formulation.

The figures highlight the potential importance of the tablet as Novo Nordisk competes in the increasingly crowded GLP-1 market, a category that has become one of the pharmaceutical industry's fastest-growing and that widely cited analyst forecasts project could surpass $100 billion in annual global sales by 2030. The pill gives the company another way to reach consumers who may prefer an oral treatment over an injectable option.

Novo Nordisk's second-quarter results also showed underlying growth. Adjusted sales increased 7% at constant exchange rates, while adjusted operating profit rose 11%. However, higher volumes were accompanied by lower realized prices, reinforcing the concern that prescription growth alone may not fully translate into stronger revenue.

Eli Lilly Keeps Competitive Pressure High

Novo Nordisk is also confronting increasingly intense competition from Eli Lilly (LLY), which gained 3.60% in Tuesday's session and outperformed Novo Nordisk by 1.75 percentage points. Lilly's Mounjaro and Zepbound franchises generated nearly $15 billion combined during the second quarter, underscoring the scale of the competitive threat. Lilly also has its own oral GLP-1 candidate, orforglipron, in late-stage development, adding a further dimension to a rivalry that has so far been led by injectable medicines.

Medicare's GLP-1 Bridge includes qualifying treatments from both companies, meaning Novo Nordisk cannot assume that greater government-supported access will automatically translate into market-share gains. The growing availability of oral and injectable treatments makes differentiation increasingly important. Novo Nordisk's Wegovy pill could become a significant competitive advantage if patients show a strong preference for tablets, but pricing and reimbursement remain critical factors.

Investors therefore face a delicate balance: greater access could stimulate demand, but government-influenced pricing and competition could restrict the financial upside from that demand.

Source: CoinCentral